The rise of ride-sharing services has increased traffic deaths by 2% to 3% in the US since 2011, equivalent to as many as 1,100 mortalities a year, according to a new study from the University of Chicago and Rice University.
How it was calculated: Researchers took statistics from the National Highway Traffic Safety Administration and compared them with the dates Uber or Lyft launched in a specific city. Then they checked accident rates in those cities relative to vehicle miles traveled. That rate shot up in San Francisco after Uber launched in 2010, a phenomenon that was replicated in other cities.
Deadheading: The increase in congestion is partly because drivers spend 40% to 60% of their time searching for passengers, a practice known as “deadheading.” On average, drivers in New York City traveled 2.8 miles between fares.
Before ride-sharing: Traffic deaths fell to their lowest number just before Uber launched in San Francisco. In 2010 there were 32,885 fatal car accidents nationwide, the lowest number since 1949. This decline halted and then reversed after the introduction of ride-sharing in US cities. However, it “may be too soon to tell whether the effect we document is a short-term adjustment or a longer-term pattern,” the researchers said.
Piling up problems: The study adds to a growing body of research on ride-sharing companies. Recent studies have found they increase congestion and cut the use of public transport. Cities are starting to respond to harms, perceived or otherwise. New York’s city council introduced a cap on ride-sharing in August, for example.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.